Friday, February 12, 2016

A game-changer for those battling melanoma

It is a good feeling when you pick a winner – whether it is the Super Bowl coin toss, Smarty Jones in the Derby (was that really 10 years ago?), or, oh, a lifesaving melanoma drug in clinical trial.

A game-changer for those battling melanoma


It is a good feeling when you pick a winner – whether it is the Super Bowl coin toss, Smarty Jones in the Derby (was that really 10 years ago?), or, oh, a lifesaving melanoma drug in clinical trial.

Following up last April’s designation as a Breakthrough Therapy, and the announcement two months ago by Merck of offering expanded access for MK-3475, yesterday the FDA announced more exciting news. The administration granted the drug, rechristened pembrolizumab, a priority review designation that will nearly halve the decision-making window. (Why the change from lambrolizumab to pembrolizumab? No idea, other than to make me learn an additional difficult-to-spell word.)

This means that the cavalry is on its way for late-stage melanoma patients. Details are sure to be forthcoming over the next few months in regards to dose, insurance coverage, availability, and oh yea, price, as I don’t think Merck is planning on handing out perm… pambro… argh… MK-3475 for free. Although, there are a lot of Ts to cross before this announcement turns into tangible treatments for public consumption.  

Still, the news is extremely positive. The Overall Response Rate from the trial cited is 41%, and 81% of the patients were alive after one year. With melanoma’s death rate reaching more than one person every HOUR in the United States, shaving four months off approval of PD-1 will give an extra 3,000 people the opportunity of a promising treatment, who otherwise probably wouldn’t see 2015. Granted, not all of these patients will respond to the drug, but some will – as will many others who cannot get access to PD-1 right now. Putting a number on “lives saved” or even affected isn’t possible, but whatever that number would be, it is significant.

This priority review is based off a single-arm study – which isn’t mine – so the data from the controlled study I am participating in may not even be reviewed until after the drug is approved. Aside from my partial response, the murmurs from the oncology, advocate, and patient worlds all indicate that the larger studies are showing the same or better results. Long-term results will be years away, but since most cancer patients don’t have that time, it is great a treatment with obvious sustainable benefits is getting prioritized review and, ultimately, approval.

If you have melanoma right now and for some reason cannot get the expanded access program, you have one job in 2014 – stay alive until Halloween. In all likelihood, the game changes then, and for once, it’s in favor of the patient.

T.J. Sharpe shares his fight against Stage 4 Melanoma in the Patient #1 blog. Read more »

We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
T.J. Sharpe is sharing his fight against Stage 4 Melanoma. A South Jersey native and Bishop Eustace graduate, he currently lives in Fort Lauderdale, FL with his wife Jennifer and children Josie and Tommy. He was Patient #1 in a clinical trial at Moffitt Cancer Center in Tampa as the first person worldwide to use this sequence of treatments to fight melanoma, and is currently in a second clinical trial at Holy Cross Hospital in Fort Lauderdale receiving Merck’s anti-PD-1 drug Lambrolizumab

The Patient #1 blog will update the progress of T.J.'s fight against cancer, and also touch on many cancer-related topics.

Follow T.J. on Twitter and Facebook. Reach T.J. at

T.J. Sharpe
Latest Health Videos
Also on
letter icon Newsletter